Antitumour drugs targeting Tau R3 VQIVYK and Cys322 Prevent Seeding of endogenous Tau aggregates by Exogenous Seeds

FEBS Journal ◽  
2021 ◽  
Author(s):  
Narendran Annadurai ◽  
Lukáš Malina ◽  
Mario Salmona ◽  
Luisa Diomede ◽  
Antonio Bastone ◽  
...  
Keyword(s):  
Antitumour Drugs

Tin-based antitumour drugs

1996 ◽  
Vol 151 ◽  
pp. 41-51 ◽  
Author(s):  
Marcel Gielen
Keyword(s):  
Antitumour Drugs

Methotrexate Loaded Solid Lipid Nanoparticles (SLN) for Effective Treatment of Carcinoma

2006 ◽  
Vol 6 (9) ◽  
pp. 2991-2995 ◽  
Author(s):  
K. Ruckmani ◽  
M. Sivakumar ◽  
P. A. Ganeshkumar
Keyword(s):  
Stearic Acid ◽  
Solid Lipid Nanoparticles ◽  
Lipid Nanoparticles ◽  
Solid Lipid ◽  
Soya Lecithin ◽  
Release Drug ◽  
Antitumour Drugs ◽  
Sodium Taurodeoxycholate ◽  
Average Size

Solid Lipid Nanoparticles (SLN) containing Methotrexate (MTX), an anticancer drug for intravenous administration was formulated and characterized. The SLN dispersions with MTX, stearic acid, and soya lecithin in the ratio of 1:4:1, 1:4:1.5, and 1:4:2, sodium taurodeoxycholate and distilled water were prepared by micro emulsification solidification method. The results show that the prepared MTX-SLN particles (with MTX–Stearic acid–Soya lecithin—1:4:2) have an average size of 270 nm with 51.3% drug entrapment. The in vitro-release was attained up to 15th h. The pharmacokinetic studyreveals that the half-life and MRT of SLNs were higher than MTX solution. The life span of EAC (Ehrlich Ascite Carcinoma) bearing mice was increased when treated with MTX-SLNs (Methotrexate nanoparticles). These results clearly indicate that SLNs are a promising sustained release drug targeting system for lipophilic antitumour drugs.

Novel Concepts in the Development of Platinum Antitumour Drugs: An Update

2004 ◽  
Vol 1 (2) ◽  
pp. 187-198 ◽  
Author(s):  
M. Fuertes ◽  
J. Castilla ◽  
Paul Nguewa ◽  
C. Alonso ◽  
J. Perez
Keyword(s):  
Antitumour Drugs

Chelating agents as antitumour drugs: Formation of chelating agents from the antitumour pro-drug, razoxane

1990 ◽  
Vol 168 (2) ◽  
pp. 283-288 ◽  
Author(s):  
Kevin B. Nolan ◽  
Terry Murphy ◽  
Richard D. Hermanns ◽  
Haji Rahoo ◽  
Andrew M. Creighton
Keyword(s):  
Chelating Agents ◽  
Antitumour Drugs

scholarly journals Contribution of H-Bonding to the Preference of Platinum Anti-Tumour Drugs for Particular Bases and Particular Cross-Links

1994 ◽  
Vol 1 (4) ◽  
pp. 311-319
Author(s):  
Giovanni Natile
Keyword(s):  
Hydrogen Bonds ◽  
Specific Binding ◽  
Strong Preference ◽  
Antitumour Drugs ◽  
Cross Links

The stereochemical factors that influence the tendencies for sequence specific binding of platinum antitumour drugs to DNA are examined. The NHs of the platinum-amine moiety can form hydrogen bonds to the O6 of guanine or to a phosphate oxygen of DNA. Modelling the stereochemistry of the NH atoms can lead to compounds with a strong preference for forming one type of adduct with DNA.

scholarly journals Repeated injection of pegylated liposomal antitumour drugs induces the disappearance of the rapid distribution phase

2008 ◽  
Vol 60 (12) ◽  
pp. 1651-1657 ◽  
Author(s):  
JingXia Cui ◽  
ChunLei Li ◽  
CaiXia Wang ◽  
YanHui Li ◽  
Lan Zhang ◽  
...  
Keyword(s):  
Repeated Injection ◽  
Antitumour Drugs ◽  
Distribution Phase

Liposomes as carriers of different new lipophilic antitumour drugs: A preliminary report

1994 ◽  
Vol 11 (3) ◽  
pp. 309-318 ◽  
Author(s):  
F. Sampedro ◽  
J. Partika ◽  
P. Santalo ◽  
A. M. Molins-Pujol ◽  
J. Bonal ◽  
...  
Keyword(s):  
Preliminary Report ◽  
Antitumour Drugs
Sign in / Sign up

Export Citation Format

Share Document